• STAT+: Pharmalittle: European regulators unlikely to approve Biogen Alzheimer's drug; U.S. to invest billions to expand Covid vaccine production

    10 days ago - By STAT

    Everyone, and welcome to the middle of the week. You made it this far, so why not continue, yes? Perhaps a cup or two of stimulation is in order. Our choice today is maple bourbon. As you know, a prescription is not required. So feel free to indulge as you attack the laundry list of meetings and deadlines that await. Meanwhile, we have once again assembled a list of tidbits for you to peruse and help you on your way. Hope you have a smashing day and, as always, do drop us a line when you hear something interesting....
    A European Medicines Agency panel notified Biogen that its Alzheimer's...
    Read more ...

     

  • STAT+: European regulators signal Biogen's new Alzheimer's therapy is unlikely to win approval

    10 days ago - By STAT

    A panel of European drug reviewers notified Biogen that its Alzheimer's treatment Aduhelm is unlikely to win approval there, the company announced Wednesday.
    Aduhelm received a “negative trend vote” from experts at the European Medicines Agency, following a type of hearing called an oral explanation. Continue to STAT+ to read the full story...
    Read more ...